HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05127226 |
|
Recruitment Status :
Active, not recruiting
First Posted : November 19, 2021
Last Update Posted : March 20, 2024
|
Sponsor:
Ionis Pharmaceuticals, Inc.
Collaborator:
Biogen
Information provided by (Responsible Party):
Ionis Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | March 2029 |
| Estimated Study Completion Date : | March 2029 |